A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro…

Overview of attention for article published in Tumori Journal, November 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#42 of 923)
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

So far, Altmetric has seen 23 tweets from 12 users, with an upper bound of 7,931 followers.

RT @TumoriJ: #WorldKidneyCancerDay @worldkidneyday Results of the BREAKPOINT Trial evaluating efficacy and safety of #cabozantinib for pat…

#WorldKidneyCancerDay @worldkidneyday Results of the BREAKPOINT Trial evaluating efficacy and safety of #cabozantinib for patients with metastatic #renalcellcarcinoma by G Procopio @gippo27, @MelClaps et al 🔗https://t.co/bzMluYCxXb… #kcsm #WorldKidneyD

RT @TumoriJ: 🎙️ #Podcast Dr Mélanie Claps and Dr Giuseppe Procopio discuss about the results of the Breakpoint Trial evaluating efficacy an…

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 19 additional tweets.